<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974203</url>
  </required_header>
  <id_info>
    <org_study_id>2021.03.3.0102</org_study_id>
    <nct_id>NCT04974203</nct_id>
  </id_info>
  <brief_title>Saliva-based COVID-19 DNA Aptamer Test</brief_title>
  <official_title>Saliva-based COVID-19 DNA Aptamer Test: Formative Usability and Internal Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achiko AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Udayana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Achiko AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to conduct formative usability and internal validation of the COVID-19 rapid&#xD;
      diagnostic test tool based on DNA aptamers, involving 200 patients to assess aspects of&#xD;
      experimental setup, testing center, testing kit configuration, designing algorithms or&#xD;
      workflows for clinical trials, and also assess initial accuracy by validating with the&#xD;
      patient's PCR test results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RT-PCR has several limitations that need to be considered in its role as a COVID-19&#xD;
      diagnostic modality, especially in areas with limited health infrastructure. Potential&#xD;
      diagnostic tests are needed that are capable of detecting results that are fast to read, can&#xD;
      be carried out in service locations with limited infrastructure, and have high accuracy. The&#xD;
      DNA Aptamers-based diagnostic test has the potential to meet these criteria, as it allows the&#xD;
      detection of infection quickly and without invasive procedures, where the examination is only&#xD;
      on a person's saliva.&#xD;
&#xD;
      The development of diagnostic tools must be well planned including the usability and internal&#xD;
      validation of the tools to be studied before they can be used in clinical trial settings or&#xD;
      diagnostic accuracy tests by involving patients in health services. This study aims to&#xD;
      conduct formative usability and internal validation of the DNA aptamer-based COVID-19 rapid&#xD;
      diagnostic test, involving 200 patients and also laboratory personnel to assess aspects of&#xD;
      experimental setup, testing center, testing kit configuration, designing algorithms or&#xD;
      workflows for testing in clinical trials, and also assess early indications of instrument&#xD;
      accuracy by validating with the patient's PCR test data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients who undertake PCR test are asked to provide saliva sample</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessors are blinded to the PCR test result</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hands-On-Time (HOT)</measure>
    <time_frame>1 month</time_frame>
    <description>Total time (seconds) spent by the Operator(s) to process one test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-To-Result (TTR)</measure>
    <time_frame>1 month</time_frame>
    <description>Instrument readout, from loading the cuvette in the spectrophotometer, up to recording the test as Positive / Negative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testing Centre First-Time-Hit percentage (FTH)</measure>
    <time_frame>1 month</time_frame>
    <description>The FTH percentage measures proportion of test kits that will be correctly processed with no single mistake, from the opening of the test kit to recording the test result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technician Subjective elements</measure>
    <time_frame>1 month</time_frame>
    <description>Aspects of the workflow liked/not liked by the technicians</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient subjective elements</measure>
    <time_frame>1 month</time_frame>
    <description>Aspects of the workflow liked/not liked by the patient during saliva collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>1 month</time_frame>
    <description>The ability of a test to correctly identify those with the disease (true positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>1 month</time_frame>
    <description>The ability of the test to correctly identify those without the disease (true negative rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>1 month</time_frame>
    <description>The proportions of positive results that are true positive results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>1 month</time_frame>
    <description>The proportions of negative results that are true negative results</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>CT Value &lt;25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CT value &lt;25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT Value 25+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CT value of 25 or higher</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with negative PCR test result</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AptameX</intervention_name>
    <description>DNA aptamer-based test using patient's saliva</description>
    <arm_group_label>CT Value 25+</arm_group_label>
    <arm_group_label>CT Value &lt;25</arm_group_label>
    <arm_group_label>Negative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-59 years old&#xD;
&#xD;
          -  Undertaking PCR swab test for screening, or&#xD;
&#xD;
          -  In-patients undertaking PCR swab test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to produce saliva&#xD;
&#xD;
          -  Refusing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Udayana University Hospital</name>
      <address>
        <city>Badung</city>
        <state>Bali</state>
        <zip>80361</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I Md A Wirawan, MD, PhD</last_name>
      <phone>081239394465</phone>
      <email>ady.wirawan@unud.ac.id</email>
    </contact>
    <investigator>
      <last_name>I Md Ady Wirawan, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Putu Ayu Swandewi Astuti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I Nyoman Sutarsa, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cokorda Agung Wahyu Purnamasidhi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ni Kadek Mulyantari, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I Made Dwi Ariawan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ni Made Suandewi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Saliva-based test</keyword>
  <keyword>DNA aptamer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will be managed by investigators only. Analyzed data or result summary will be shared to related researchers or other parties</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

